Increased tumor immunity in mice inoculated with muconomycin A-treated B16 melanoma cells.
B16 melanoma cells were treated in vitro with muconomycin A, a long-lasting inhibitor of protein and glycoprotein synthesis, to reduce cellular sialic acid. Two i.p. inoculations of 10(7) muconomycin-treated cells into female C57BL/6 mice, followed by challenge with homologous live cells, resulted in a significant decrease in tumor incidence when compared to the results of inoculation with untreated cells (p less than 0.01). Inoculation of mice with cells treated with neuraminidase resulted in little or no decrease in tumor incidence. Effective immunity was dependent on the number of cells injected and was found only with the i.p. route of inoculation into female mice.
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D002452:Cell Count; D002478:Cells, Cultured; D004640:Emetine / Q000494:pharmacology; D005260:Female; D007109:Immunity; D007274:Injections, Intraperitoneal; D008297:Male; D008545:Melanoma / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology; D009439:Neuraminidase / Q000494:pharmacology; D012717:Sesquiterpenes / Q000494:pharmacology*; D012737:Sex Factors; D012794:Sialic Acids / Q000378:metabolism; D014255:Trichothecenes / Q000494:pharmacology*
D000951:Antigens, Neoplasm; D012717:Sesquiterpenes; D012794:Sialic Acids; D014255:Trichothecenes; D009439:Neuraminidase; D004640:Emetine